Methyl Alcohol

Methyl Alcohol

SCHEMBL2298111

CC(C)(C)OC(=O)NCC=O.CO

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
EPHX1 P07099 1/20 0.42
CTSK P43235 3/20 0.41
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
CA12 O43570 4/20 0.39
CA9 Q16790 2/20 0.39
CA7 P43166 2/20 0.38
PTPN11 Q06124 1/20 0.38
MALT1 Q9UDY8 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
CA14 Q9ULX7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248984 0.98 TDP1 (0.48) TDP1MAOAMAOBMEN1GAA
Pyridine SCHEMBL27547036 0.87 CYP17A1 (0.41) TDP1MAOAMAOBMEN1GAA
SCHEMBL18867335 0.85 MAOA (0.44) TDP1MAOAMAOBMEN1GAA
SCHEMBL14539883 0.84 TDP1 (0.53) TDP1MAOAMAOBMEN1GAA
SCHEMBL18487257 0.83 TDP1 (0.50) TDP1MAOAMAOBMEN1GAA
SCHEMBL18262010 0.83 TDP1 (0.50) TDP1MAOAMAOBMEN1GAA
SCHEMBL2404127 0.83 TDP1 (0.50) TDP1MAOAMAOBMEN1GAA
SCHEMBL18262007 0.83 TDP1 (0.50) TDP1MAOAMAOBMEN1GAA
SCHEMBL7963255 0.81 TDP1 (0.48) TDP1MAOAMAOBMEN1GAA
SCHEMBL3341020 0.80 TDP1 (0.67) TDP1MAOAMAOBMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351567-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS DONG A ST CO LTD (KR) 2017-11-22 EP disclosed
EP-2142519-B1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY DONG A PHARM CO LTD (KR) 2014-09-24 EP disclosed
US-8440669-B2 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients DONG-A PHARMACEUTICAL CO. LTD. (KR) 2013-05-14 US disclosed
US-8030315-B2 DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity DONG-A PHARM. CO., LTD. (KR) 2011-10-04 US disclosed
US-20110201624-A1 Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients DONG-A PHARMACEUTICAL. CO., LTD (KR) 2011-08-18 US disclosed
EP-2351567-A2 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS Dong-A Pharmaceutical Co., Ltd. (KR) 2011-08-03 EP disclosed
US-20100120790-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY DONG-A PHARM. CO., LTD (KR) 2010-05-13 US disclosed
EP-2142519-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY Dong-A Pharm.Co., Ltd. (KR) 2010-01-13 EP disclosed
WO-2008130151-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY DONG-A PHARM. CO., LTD. (KR) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120790-A1 DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY DPP4, DPP7, DPP3 TDP1 1567/4885MAOA 1849/4885MAOB 1243/4885
US-20110201624-A1 Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients DPP4, DPP3, DPP7 TDP1 1880/4885MAOA 2496/4885MAOB 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.